<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Noseda, Roberta</dc:creator>
  <dc:creator>Ripellino, Paolo</dc:creator>
  <dc:creator>Ghidossi, Sara</dc:creator>
  <dc:creator>Bertoli, Raffaela</dc:creator>
  <dc:creator>Ceschi, Alessandro</dc:creator>
  <dc:date>2021-09-14</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré  syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA,  FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral  vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95%  confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were  performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP,  and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other  viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over  the full database (ROR 1.12, 95%CI 1.07–1.17), in males (ROR 1.65, 95%CI 1.54–1.78) and in age subgroups 65–74 years (ROR  1.21, 95%CI 1.05–1.39) and ≥75 years (ROR 1.84, 95%CI 1.52–2.22). Albeit not proving causation, these findings might support  clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19  vaccines.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319331</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1319331</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319331/files/Ceschi_v_2021.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines9091022</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319331</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Vaccines / Siddappa, N.. - MDPI. - 2021, vol. 9, no. 9, p. 7</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Acute inflammatory neuropathy</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">COVID-19 vaccines</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">VigiBase</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Safety</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Disproportionality</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Reporting of acute inflammatory neuropathies with COVID-19 vaccines : subgroup disproportionality analyses in VigiBase</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
